# Prolynx

> Prolynx is an Emeryville biotechnology company developing hydrogel and linker-based drug delivery systems intended to make obesity medicines last a month or more between injections. Its lead candidate, PLX-821, is a long-acting semaglutide formulation; the company is also developing dual and triple incretin agonists, amylin programs and combinations. The approach has published mouse data, while the obesity portfolio remains in preclinical development.

- **Founded:** 2009
- **Headquarters:** Emeryville, United States
- **Founders:** Daniel V. Santi (Co-founder; former Chief Technical and Scientific Officer), Gary W. Ashley (Co-founder; chemist)
- **Products:** PLX-821, Ultra-long-acting metabolic pipeline, Hydrogel-microsphere and tunable linker platform, PLX038
- **Notable:** Published a 2017 hydrogel-microsphere GLP-1 delivery study in ACS Chemical Biology., Completed a Phase 1 study of the earlier oncology prodrug PLX038 in advanced solid tumors, according to ClinicalTrials.gov., Published 2024 PNAS mouse data on a monthly semaglutide formulation and human pharmacokinetic simulations.

## Products & services

- **PLX-821** — Lead hydrogel-microsphere semaglutide candidate for obesity and type 2 diabetes, designed for once-monthly administration; preclinical program.
- **Ultra-long-acting metabolic pipeline** — Preclinical dual and triple agonist, amylin and combination programs designed around the same controlled-release architecture, with potential dosing intervals up to 90 days.
- **Hydrogel-microsphere and tunable linker platform** — Degradable tetra-PEG hydrogel microspheres hold a drug through self-cleaving linkers that govern release kinetics and gradually free the active payload.
- **PLX038** — Earlier PEGylated SN-38 oncology prodrug studied in Phase 1 and Phase 1/2 trials; a distinct formulation from the obesity hydrogel program.

## Achievements

- Published a 2017 hydrogel-microsphere GLP-1 delivery study in ACS Chemical Biology.
- Completed a Phase 1 study of the earlier oncology prodrug PLX038 in advanced solid tumors, according to ClinicalTrials.gov.
- Published 2024 PNAS mouse data on a monthly semaglutide formulation and human pharmacokinetic simulations.
- Raised a $70 million Series A in December 2025 to advance an obesity and metabolic-disease portfolio.

## Latest updates

- **2026-07** — Named Simon Harnest chief financial officer and Amer Mirza chief scientific officer as metabolic candidates moved toward IND-enabling studies.
- **2025-12** — Closed a $70 million Series A and appointed Chris Boulton chief executive officer.
- **2024-12** — Announced publication of monthly semaglutide preclinical results in PNAS.

## Links

- Website: https://www.prolynxinc.com/
- LinkedIn: https://www.linkedin.com/company/prolynx-inc
- Twitter/X: https://x.com/ProLynxInc
- Bluesky: https://bsky.app/profile/prolynx.bsky.social

---

Profile page: https://yespress.io/prolynx
Published by YesPress — https://yespress.io
Last updated: 2026-09-28